Effects of age and sex on clinical high-risk for psychosis in the community

Table 4 Frequency of clinical high risk criteria in age groups and sexes, n (% of group)

	Any CHR criterion	Any EPA criterion	COPER	COGDIS	APSS	BIPSS	GRDS, only by family history
8-12 yr	7 (6.0)	5 (4.3)	2 (1.7)	1 (0.9)	4 (3.4)	0	0
13-15 yr	5 (7.2)	4 (5.8)	3 (4.3)	3 (4.3)	1 (1.4)	0	0
16-17 yr	9 (4.7)	1 (0.5)	9 (4.7)	1 (0.5)	0	0	0
18-19 yr	5 (3.0)	3 (1.8)	4 (2.4)	3 (1.8)	1 (0.6)	0	0
20-24 yr	19 (3.9)	11 (2.2)	12 (2.4)	3 (0.6)	8 (1.8)	1 (0.2)	0
25-29 yr	4 (1.3)	1 (0.3)	3 (0.9)	0	1 (0.3)	0	0
30-40 yr	33 (2.1)	13 (0.8)	30 (1.9)	10 (0.6)	5 (0.3)	0	0
Male	29 (1.9)	13 (0.8)	22 (1.4)	6 (0.4)	9 (0.6)	0	0
Female	53 (3.9)	25 (1.8)	41 (3.0)	15 (1.1)	11 (0.8)	1 (0.1)	0
Total	82 (2.8)	38 (1.3)	63 (2.2)	21 (0.7)	20 (0.7)	1 (0.03)	0

CHR: Clinical high risk; EPA: European Psychiatric Association; COPER: Cognitive-Perceptive Basic Symptoms; COGDIS: Cognitive Disturbances; APSS: Attenuated Psychotic Symptoms Syndrome; BIPSS: Brief Intermittent Psychotic Symptoms Syndrome; GRDS: Genetic Risk and Deterioration Syndrome.